Havas Health, part of Havas Group, is a global communications company focused on health and wellness communications and cross stakeholder strategy, while Vencore supplies defence-grade analytics to the Department of Defense.

As part of the new venture, HVH is launching its first service offering: enabling biopharma commercial leaders to find undiagnosed patients with a rare disease. HVH collects, aggregates and analyses the journeys of known patients to inform early diagnosis and intervention of undiagnosed patients with a rare disease at the MSA (metropolitan statistical area), postcode or physician level. 

The joint venture will be led by Steve Costalas from Vencore (CEO) and Jeff Ceitlin from Havas Health (CCO). 

"This joint venture gives our proven defense-grade patient finder technology increased breadth and scale to better serve the pharmaceutical industry," said Costalas.  "Our potentially life-saving analytical tools will assist the earlier identification and diagnosis of disease in patients across the country."